Coya Therapeutics, Inc. recently announced the issuance of a U.S. patent for its investigational ready-to-use liquid formulation of IL-2. The patent, numbered US 12,312,389 B2, covers methods of producing highly stable liquid formulations of IL-2, also known as aldesleukin. This development marks a significant milestone for Coya, as the patent is part of a broader intellectual property portfolio that includes combinations with other biologics, such as CTLA-4 Ig and GLP-1 agonists. The company plans to continue expanding its IP portfolio and is on track to submit an IND for a combination therapy involving low-dose rhIL-2 and CTLA4-Ig by the end of June, aimed at initiating a Phase 2b study in ALS patients.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602775188) on June 02, 2025, and is solely responsible for the information contained therein.